Stockreport

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience, Inc.  (ANRO) 
PDF — Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies —— Trial design [Read more]